157 related articles for article (PubMed ID: 27566090)
21. Complete remission of unresectable hepatocellular carcinoma treated with reduced dose of sorafenib: a case report.
Wang SX; Byrnes A; Verma S; Pancoast JR; Rixe O
Target Oncol; 2010 Mar; 5(1):59-63. PubMed ID: 20309643
[TBL] [Abstract][Full Text] [Related]
22. Sorafenib-associated remission of psoriasis in hypernephroma: case report.
Fournier C; Tisman G
Dermatol Online J; 2010 Feb; 16(2):17. PubMed ID: 20178713
[TBL] [Abstract][Full Text] [Related]
23. A preclinical evaluation of a novel multikinase inhibitor, SKLB-329, as a therapeutic agent against hepatocellular carcinoma.
Zhong L; Fu XY; Zou C; Yang LL; Zhou S; Yang J; Tang Y; Cheng C; Li LL; Xiang R; Chen LJ; Chen YZ; Wei YQ; Yang SY
Int J Cancer; 2014 Dec; 135(12):2972-83. PubMed ID: 24789676
[TBL] [Abstract][Full Text] [Related]
24. Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment.
Horwitz E; Stein I; Andreozzi M; Nemeth J; Shoham A; Pappo O; Schweitzer N; Tornillo L; Kanarek N; Quagliata L; Zreik F; Porat RM; Finkelstein R; Reuter H; Koschny R; Ganten T; Mogler C; Shibolet O; Hess J; Breuhahn K; Grunewald M; Schirmacher P; Vogel A; Terracciano L; Angel P; Ben-Neriah Y; Pikarsky E
Cancer Discov; 2014 Jun; 4(6):730-43. PubMed ID: 24687604
[TBL] [Abstract][Full Text] [Related]
25. Sorafenib enhances proteasome inhibitor-mediated cytotoxicity via inhibition of unfolded protein response and keratin phosphorylation.
Honma Y; Harada M
Exp Cell Res; 2013 Aug; 319(14):2166-78. PubMed ID: 23727131
[TBL] [Abstract][Full Text] [Related]
26. Angiogenic Response following Radioembolization: Results from a Randomized Pilot Study of Yttrium-90 with or without Sorafenib.
Lewandowski RJ; Andreoli JM; Hickey R; Kallini JR; Gabr A; Baker T; Kircher S; Salem R; Kulik L
J Vasc Interv Radiol; 2016 Sep; 27(9):1329-1336. PubMed ID: 27266362
[TBL] [Abstract][Full Text] [Related]
27. Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy.
Park JG
Clin Mol Hepatol; 2015 Sep; 21(3):287-94. PubMed ID: 26527250
[TBL] [Abstract][Full Text] [Related]
28. Sorafenib and DE605, a novel c-Met inhibitor, synergistically suppress hepatocellular carcinoma.
Jiang X; Feng K; Zhang Y; Li Z; Zhou F; Dou H; Wang T
Oncotarget; 2015 May; 6(14):12340-56. PubMed ID: 25895026
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of combination therapy with everolimus and sorafenib for recurrence of hepatocellular carcinoma after liver transplantation.
De Simone P; Crocetti L; Pezzati D; Bargellini I; Ghinolfi D; Carrai P; Leonardi G; Della Pina C; Cioni D; Pollina L; Campani D; Bartolozzi C; Lencioni R; Filipponi F
Transplant Proc; 2014; 46(1):241-4. PubMed ID: 24507059
[TBL] [Abstract][Full Text] [Related]
30. Synergistic effect of sorafenib and vitamin K on suppression of hepatocellular carcinoma cell migration and metastasis.
Ha TY; Hwang S; Hong HN; Choi YI; Yoon SY; Won YJ; Song GW; Kim N; Tak E; Ryoo BY
Anticancer Res; 2015 Apr; 35(4):1985-95. PubMed ID: 25862851
[TBL] [Abstract][Full Text] [Related]
31. [Complete response after sorafenib therapy plus zoledronic acid for advanced hepatocellular carcinoma with bone metastasis - a case report].
Natori T; Yamaguchi M
Gan To Kagaku Ryoho; 2013 May; 40(5):635-7. PubMed ID: 23863589
[TBL] [Abstract][Full Text] [Related]
32. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
[TBL] [Abstract][Full Text] [Related]
33. Exceptional serological and radiological response to sorafenib in 2 patients with advanced hepatocellular carcinoma and chronic hepatitis C viral infection: case report and review of the literature.
Atkin C; Earwaker P; Pallan A; Shetty S; Punia P; Ma YT
BMC Gastroenterol; 2017 Feb; 17(1):30. PubMed ID: 28193171
[TBL] [Abstract][Full Text] [Related]
34. CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer.
Gao DY; Lin TsT; Sung YC; Liu YC; Chiang WH; Chang CC; Liu JY; Chen Y
Biomaterials; 2015 Oct; 67():194-203. PubMed ID: 26218745
[TBL] [Abstract][Full Text] [Related]
35. Reproducible complete remission of advanced hepatocellular carcinoma with sorafenib in combination with clopidogrel.
Tan-Shalaby JL
BMJ Case Rep; 2014 Sep; 2014():. PubMed ID: 25178887
[TBL] [Abstract][Full Text] [Related]
36. Sorafenib: the gold standard therapy in advanced hepatocellular carcinoma and beyond.
Gadaleta-Caldarola G; Divella R; Mazzocca A; Infusino S; Ferraro E; Filippelli G; Daniele A; Sabbà C; Abbate I; Brandi M
Future Oncol; 2015; 11(16):2263-6. PubMed ID: 26260805
[No Abstract] [Full Text] [Related]
37. Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy.
Estfan B; Byrne M; Kim R
Am J Clin Oncol; 2013 Aug; 36(4):319-24. PubMed ID: 22547010
[TBL] [Abstract][Full Text] [Related]
38. A polymeric nanoparticle formulation of curcumin in combination with sorafenib synergistically inhibits tumor growth and metastasis in an orthotopic model of human hepatocellular carcinoma.
Hu B; Sun D; Sun C; Sun YF; Sun HX; Zhu QF; Yang XR; Gao YB; Tang WG; Fan J; Maitra A; Anders RA; Xu Y
Biochem Biophys Res Commun; 2015 Dec; 468(4):525-32. PubMed ID: 26482853
[TBL] [Abstract][Full Text] [Related]
39. Knockout of ADAM10 enhances sorafenib antitumor activity of hepatocellular carcinoma in vitro and in vivo.
Zhang W; Liu S; Liu K; Ji B; Wang Y; Liu Y
Oncol Rep; 2014 Nov; 32(5):1913-22. PubMed ID: 25176394
[TBL] [Abstract][Full Text] [Related]
40. Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: treatment outcome and prognostic factors.
Sohn W; Paik YH; Cho JY; Lim HY; Ahn JM; Sinn DH; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
J Hepatol; 2015 May; 62(5):1112-21. PubMed ID: 25514557
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]